Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mHAIC + lenvatinib + camrelizumab for advanced unresectable hepatocellular carcinoma
ChiCTR2300067295Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Yanbian University
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, tegafur, lenvatinib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by The Affiliated Hospital of Yanbian University. Primary endpoints: RECIST 1.1 response assessment and Progression-free survival. Started Jan 2023; status: recruiting.
02
Drugs
oxaliplatintegafurlenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300067295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067295.